Galapagos NV (GLPG)
- Previous Close
28.63 - Open
28.54 - Bid 28.74 x 200
- Ask 28.80 x 200
- Day's Range
28.34 - 28.86 - 52 Week Range
28.33 - 45.21 - Volume
74,898 - Avg. Volume
126,509 - Market Cap (intraday)
1.921B - Beta (5Y Monthly) 0.02
- PE Ratio (TTM)
-- - EPS (TTM)
-0.06 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
41.91
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
www.glpg.comRecent News: GLPG
Performance Overview: GLPG
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GLPG
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GLPG
Valuation Measures
Market Cap
1.87B
Enterprise Value
-2.06B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.35
Price/Book (mrq)
0.63
Enterprise Value/Revenue
-8.59
Enterprise Value/EBITDA
-40.35
Financial Highlights
Profitability and Income Statement
Profit Margin
88.31%
Return on Assets (ttm)
-1.11%
Return on Equity (ttm)
-0.15%
Revenue (ttm)
239.72M
Net Income Avi to Common (ttm)
-3.99M
Diluted EPS (ttm)
-0.06
Balance Sheet and Cash Flow
Total Cash (mrq)
3.68B
Total Debt/Equity (mrq)
0.34%
Levered Free Cash Flow (ttm)
-124.2M